4D Molecular Therapeutics (NASDAQ:FDMT) Given Sell (E+) Rating at Weiss Ratings

Weiss Ratings restated their sell (e+) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a report published on Thursday,Weiss Ratings reports.

A number of other research firms have also recently weighed in on FDMT. Royal Bank of Canada cut their price objective on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating on the stock in a report on Monday, March 3rd. BMO Capital Markets cut shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $40.00 to $15.00 in a research report on Monday, January 13th. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Monday, March 3rd. Morgan Stanley cut their target price on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a research report on Monday, January 13th. Finally, Leerink Partners decreased their target price on 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a research report on Monday, January 13th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $26.71.

4D Molecular Therapeutics Trading Down 5.0 %

4D Molecular Therapeutics stock opened at $3.25 on Thursday. The company has a fifty day simple moving average of $3.65 and a 200-day simple moving average of $5.71. The stock has a market cap of $150.48 million, a P/E ratio of -1.14 and a beta of 2.89. 4D Molecular Therapeutics has a 12-month low of $2.24 and a 12-month high of $28.93.

4D Molecular Therapeutics (NASDAQ:FDMT) last announced its quarterly earnings results on Friday, February 28th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10). As a group, sell-side analysts forecast that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. KLP Kapitalforvaltning AS purchased a new position in shares of 4D Molecular Therapeutics in the 4th quarter valued at approximately $48,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in 4D Molecular Therapeutics in the 4th quarter valued at $50,000. PNC Financial Services Group Inc. increased its stake in 4D Molecular Therapeutics by 66.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock valued at $51,000 after buying an additional 3,630 shares during the period. Daiwa Securities Group Inc. raised its position in 4D Molecular Therapeutics by 5,291.8% during the 4th quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company’s stock worth $55,000 after buying an additional 9,737 shares during the last quarter. Finally, Velan Capital Investment Management LP acquired a new stake in shares of 4D Molecular Therapeutics in the 4th quarter worth $56,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.